An exploratory study of the safety, tolerability, pharmacokinetics and potential effectiveness of AVI-4020 injection in patients presenting with presumptive acute neuroinvasive West Nile virus (WNV) disease

Trial Profile

An exploratory study of the safety, tolerability, pharmacokinetics and potential effectiveness of AVI-4020 injection in patients presenting with presumptive acute neuroinvasive West Nile virus (WNV) disease

Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2012

At a glance

  • Drugs AVI 4020 (Primary)
  • Indications West Nile virus infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 02 Aug 2012 Lead trial centre (Sarepta Therapeutics) added as reported by ClinicalTrials.gov record.
    • 03 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top